HaroldJohnBursteinMD

Oncology • Boston, MA

Breast Cancer, Hematologic Oncology

Associate Professor of Medicine, Dana-Farber Cancer Institute

Join to view full profile

Dr. Burstein is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Burstein's full profile

Already have an account?

Office
450 Brookline Ave
Dana Farber Cancer Institute
Boston, MA 02115
Phone+1 617-632-2624

Fax+1 617-632-1930
Is this information wrong?

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1996 - 1999
Massachusetts General HospitalResidency, Internal Medicine, 1994 - 1996
Harvard Medical SchoolClass of 1994

Certifications & Licensure

FL State Medical License 2022 - Present
CT State Medical License 2022 - 2025
MA State Medical License 1996 - 2025
RI State Medical License 2022 - 2024
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2009-2014
America's Top Doctors for Cancer Castle Connolly, 2005-2013
Boston Magazine Castle Connolly, 2008, 2010-2013
Fellow (FASCO) American Society of Clinical Oncologists, 2012
Whos Who in Medicine and Healthcare Marquis Whos Who
Super Doctor SuperDoctors.com
Join now to see all

Clinical Trials

Rebeccamycin Analogue in Treating Women With Stage IIIB or Stage IV Breast Cancer Start of enrollment: 2000 Mar 01
Completed
Phase 2
Bevacizumab Plus Vinorelbine in Treating Patients With Stage IV Breast Cancer Start of enrollment: 2001 Mar 01
Completed
Phase 2
Safety And Efficacy Study Of The Combination Of CpG 7909 And Herceptin In Patients With Metastatic Breast Cancer Start of enrollment: 2001 Oct 01
Completed
Phase 1, Phase 2
Metronomic Low-Dose Cyclophosphamide and Methotrexate With or Without Bevacizumab in Treating Women With Metastatic Breast Cancer Start of enrollment: 2003 Jul 01
Completed
Phase 2
Bevacizumab With or Without Cyclophosphamide and Methotrexate: A Pilot Study in Women With Operable Breast Cancer Start of enrollment: 2005 Jun 01
Completed
Not Applicable
Neoadjuvant Therapy With Herceptin and Taxol for Breast Cancer Start of enrollment: 1999 Mar 01
Completed
Phase 2
Trastuzumab in Combination With Vinorelbine or Taxane-Based Chemotherapy in Patients With Metastatic Breast Cancer Start of enrollment: 2001 Aug 01
Completed
Phase 3
Pegfilgrastim and Darbepoetin Alfa in Support of Adjuvant Chemotherapy for Breast Cancer Start of enrollment: 2003 Jul 01
Completed
Phase 2
A Phase II Study of AZD2171 in Breast Cancer Stage IV (10006202) Start of enrollment: 2005 Sep 01
Completed
Phase 2
Dose Dense Abraxane in Adjuvant Chemotherapy for Breast Cancer Start of enrollment: 2006 Mar 01
Completed
Not Applicable
Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive Start of enrollment: 2006 Sep 15
Completed
Phase 3
Letrozole in Preventing Cancer in Postmenopausal Women Who Have Received 4-6 Years of Hormone Therapy for Hormone Receptor-Positive, Lymph Node-Positive, Early-Stage Breast Cancer Start of enrollment: 2007 Aug 01
Completed
Phase 3
Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer Start of enrollment: 2008 May 15
Active, not recruiting
Phase 3
Bevacizumab in Combination With Vinorelbine and Trastuzumab for HER2-Positive, Metastatic Breast Cancer Start of enrollment: 2008 May 01
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

Optimizing Postneoadjuvant Treatment in Patients With Early Breast Cancer Achieving Pathologic Complete Response.
Carmine Valenza, Dario Trapani, Sibylle Loibl, Stephen K L Chia, Giuseppe Curigliano, Harold J Burstein> ;Journal of Clinical Oncology. 2024 Apr 3
PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Horm...
Erica L Mayer, Yue Ren, Nikhil Wagle, Reshma Mahtani, Cynthia Ma, Angela DeMichele, Massimo Cristofanilli, Jane Meisel, Kathy D Miller, Yara Abdou, Elizabeth C Riley, ...> ;Journal of Clinical Oncology. 2024 Mar 21
Endocrine and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer-Capivasertib-Fulvestrant: ASCO...
Shatsky, R. A., Harold J Burstein, Angela DeMichele, Lesley Fallowfield, Mark R Somerfield, N Lynn Henry, > ;Journal of Clinical Oncology. 2024 Apr 20
ASO Visual Abstract: Defining the Biology of Estrogen Receptor-Low Positive Breast Cancer.
Higgins, T., Harrison, B., Giordano, J., McGrath, M., Kantor, O., Burstein, H., Schnitt, S., Rahman, T., Vora, H., Garrido-Castro, A., Tolaney, S., Meric-Bernstam, F.,...> ;Annals of Surgical Oncology. 2024 Apr 1
1 citations
Defining the Biology of Estrogen Receptor-Low-Positive Breast Cancer.
Higgins, T., Harrison, B., Giordano, J., McGrath, M., Kantor, O., Burstein, H., Schnitt, S., Rahman, T., Vora, H., Garrido-Castro, A., Tolaney, S., Meric-Bernstam, F.,...> ;Annals of Surgical Oncology. 2024 Apr 1
A randomized phase II study of metronomic cyclophosphamide and methotrexate (CM) with or without bevacizumab in patients with advanced breast cancer.
Erica L Mayer, Nabihah Tayob, Siyang Ren, Jennifer J Savoie, David R Spigel, Howard A Burris 3rd, Paula D Ryan, Lyndsay N Harris, Eric P Winer, Harold J Burstein> ;Breast Cancer Research and Treatment. 2024 Feb 1
1 citations
Impact of BMI in Patients With Early Hormone Receptor-Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial.
Georg Pfeiler, Dominik Hlauschek, Erica L Mayer, Christine Deutschmann, Stephanie Kacerovsky-Strobl, Miguel Martin, Jane Lowe Meisel, Nicholas Zdenkowski, Sibylle Loib...> ;Journal of Clinical Oncology. 2023 Nov 20
35 citations
ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer.
P Tarantino, G Viale, M F Press, X Hu, F Penault-Llorca, A Bardia, A Batistatou, H J Burstein, L A Carey, J Cortes, C Denkert, V Diéras, W Jacot, A K Koutras, A Lebeau...> ;Annals of Oncology. 2023 Aug 1
12 citations
Testing forMutations to Guide Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Rapid R...
Harold J Burstein, Angela DeMichele, Mark R Somerfield, N Lynn Henry> ;Journal of Clinical Oncology. 2023 Jun 20
Identifying Patterns and Barriers in OncotypeDX Recurrence Score Testing in Older Patients With Early-Stage, Estrogen Receptor-Positive Breast Cancer: Implications for...
Dario Trapani, Qingchun Jin, Caroline C Block, Rachel A Freedman, Nancy U Lin, Elizabeth A Mittendorf, Tari A King, Susan C Lester, Jane E Brock, Nabihah Tayob, Craig ...> ;JCO Oncology Practice. 2023 Aug 1
8 citations
The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer.
Albert Grinshpun, Sara M Tolaney, Harold J Burstein, Rinath Jeselsohn, Erica L Mayer> ;NPJ Breast Cancer. 2023 Mar 22
3 citations
Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030.
Heather A Parsons, Timothy Blewett, Xiangying Chu, Sainetra Sridhar, Katheryn Santos, Kan Xiong, Vandana G Abramson, Ashka Patel, Ju Cheng, Adam Brufsky, Justin Rhoade...> ;Medrxiv. 2023 Mar 8
35 citations
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial.
Tolaney, S., Tarantino, P., Graham, N., Tayob, N., Parè, L., Villacampa, G., Dang, C., Yardley, D., Moy, B., Marcom, P., Albain, K., Rugo, H., Ellis, M., Shapira, I., ...> ;The Lancet. Oncology. 2023 Mar 1
Escalation, De-escalation, Adaptation, Speciation, Customization: The New Approaches to Breast Cancer.
Harold J Burstein> ;Hematology/oncology Clinics of North America. 2023 Feb 1
28 citations
Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials.
Olivia Pagani, Barbara A Walley, Gini F Fleming, Marco Colleoni, István Láng, Henry L Gomez, Carlo Tondini, Harold J Burstein, Matthew P Goetz, Eva M Ciruelos, Vered S...> ;Journal of Clinical Oncology. 2023 Mar 1
13 citations
Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT.
Prudence A Francis, Gini F Fleming, István Láng, Eva M Ciruelos, Hervé R Bonnefoi, Meritxell Bellet, Antonio Bernardo, Miguel A Climent, Silvana Martino, Begoña Bermej...> ;Journal of Clinical Oncology. 2023 Mar 1
4 citations
Treatment discontinuation, patient-reported toxicities and quality-of-life by age following trastuzumab emtansine or paclitaxel/trastuzumab (ATEMPT).
Tal Sella, Yue Zheng, Nabihah Tayob, Kathryn J Ruddy, Rachel A Freedman, Chau Dang, Denise Yardley, Steven J Isakoff, Vicente Valero, Michelle DeMeo, Harold J Burstein...> ;NPJ Breast Cancer. 2022 Nov 30
3 citations
Postneoadjuvant treatment for triple-negative breast cancer.
Dario Trapani, Emanuela Ferraro, Federica Giugliano, Luca Boscolo Bielo, Giuseppe Curigliano, Harold J Burstein> ;Current Opinion in Oncology. 2022 Nov 1
1 citations
'ADVANCE' (a pilot trial) ADjuVANt chemotherapy in the elderly: Developing and evaluating lower-toxicity chemotherapy options for older patients with breast cancer.
Rachel A Freedman, Tianyu Li, Mina S Sedrak, Judith O Hopkins, Nabihah Tayob, Meredith G Faggen, Natalie F Sinclair, Wendy Y Chen, Heather A Parsons, Erica L Mayer, Pa...> ;Journal of Geriatric Oncology. 2023 Jan 1
ASO Visual Abstract: Expanding Staging Criteria in T1-2N0 Hormone Receptor-Positive Breast Cancer Patients Enrolled in TAILORx.
Olga Kantor, Harold J Burstein, Tari A King, Steven Shak, Christy A Russell, Armando E Giuliano, Gabriel N Hortobagyi, Eric P Winer, Larissa A Korde, Joseph A Sparano,...> ;Annals of Surgical Oncology. 2022 Dec 1
Expanding the Staging Criteria for T1-2N0 Hormone-Receptor Positive Breast Cancer Patients Enrolled in TAILORx.
Olga Kantor, Harold J Burstein, Tari A King, Steven Shak, Christy A Russell, Armando E Giuliano, Gabriel N Hortobagyi, Eric P Winer, Larissa A Korde, Joseph A Sparano,...> ;Annals of Surgical Oncology. 2022 Dec 1
ASO Visual Abstract: Sentinel Lymph Node Biopsy Alone is Adequate for Chemotherapy Decisions in Postmenopausal Early-Stage, Hormone-Receptor-Positive, HER2-Negative Br...
Olga Kantor, Anna Weiss, Harold J Burstein, Elizabeth A Mittendorf, Tari A King> ;Annals of Surgical Oncology. 2022 Nov 1
21 citations
Risk-adapted modulation through de-intensification of cancer treatments: an ESMO classification.
D Trapani, M A Franzoi, H J Burstein, L A Carey, S Delaloge, N Harbeck, D F Hayes, K Kalinsky, L Pusztai, M M Regan, I Sestak, T Spanic, J Sparano, S Jezdic, N Cherny,...> ;Annals of Oncology. 2022 Jul 1
1 citations
Sentinel Lymph Node Biopsy Alone is Adequate for Chemotherapy Decisions in Postmenopausal Early-Stage Hormone-Receptor-Positive, HER2-Negative Breast Cancer with One t...
Olga Kantor, Anna Weiss, Harold J Burstein, Elizabeth A Mittendorf, Tari A King> ;Annals of Surgical Oncology. 2022 Nov 1
4 citations
A look at current and potential treatment approaches for hormone receptor-positive, HER2-negative early breast cancer.
Nadia Harbeck, Harold J Burstein, Sara A Hurvitz, Stephen Johnston, Gregory A Vidal> ;Cancer. 2022 Jun 1
Join now to see all

Journal Articles

Adjuvant Capecitabine in Triple-Negative Breast Cancer
Harold Burstein, MD, JAMA
Functional Decline and Resilience in Older Women Receiving Adjuvant Chemotherapy for Breast Cancer
Aminah Jatoi, Antonio C Wolff, Harvey Jay Cohen, Rachel A Freedman, Gustav Magrinat, Julie Gralow, Gretchen Kimmick, Heidi D Klepin, Harold Burstein, Hyman Muss, Jeann..., Journal of the American Geriatrics Society

Lectures

Genomic Profiling in ER-Positive Breast Cancer, From MINDACT to TAILORx
ASCO Annual Meeting 2019 - Chicago, IL - 6/3/2019
Breast Cancer, New Horizons, Current Controversies
Harvard Medical School, Boston, Massachusetts - 7/11/2013
The New York Metropolitan Breast Cancer Group 40th Annual Symposium: Breast Cancer 2013
The New York Academy of Medicine, New York, New York - 2/2/2013
Breast Cancer, New Horizons, Current Controversies
Harvard Medical School, Boston, Massachusetts - 7/12/2012
18th Annual Network of Oncology Clinicians & Researchers (NOCR) Meeting
Imedex, Las Vegas, Nevada - 2/9/2012
Join now to see all

Press Mentions

1 NCCN Guidelines for Patients® Inflammatory Breast Cancer, 2023March 23rd, 2023
The FDA Requires Mammography Providers to Notify Women of Their Breast Density to Help Detect Breast Cancer SoonerMarch 9th, 2023
More Women with Breast Cancer Could Survive Harsher Radiation, Study SaysFebruary 15th, 2023
Join now to see all